Global Idiopathic Pulmonary Fibrosis Treatment Market

Global Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Growth Analysis, By Type(Pirfenidone and nintedanib), By Distribution channel(Hospital pharmacies, retail pharmacies and online providers) - Industry Forecast 2023-2030


Report ID: SQMIG35I2261 | Region: Global | Published Date: October, 2023 | Pages: 157 | Tables: 60 | Figures: 75

Global Idiopathic Pulmonary Fibrosis Treatment Market Insights

Global Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 15.2 billion in 2021 and is poised to grow from USD 16.13 billion in 2022 to USD 25.96 billion by 2030, at a CAGR of 6.13% during the forecast period (2023-2030). 

The global idiopathic pulmonary fibrosis treatment market has experienced significant growth in recent years. The primary reason behind the market growth is growing population, and rising awareness of diseases. Idiopathic pulmonary fibrosis(IPF) is the most common type of pulmonary fibrosis. It’s a disease that causes scarring of the lungs. Scarring causes difficulty in the lungs and makes it difficult to breathe. The landscape of treatment for idiopathic pulmonary fibrosis includes pharmacological interventions, such as Nintedanib and Pirfenidone, which are approved by regulatory bodies for showing progress in disease. In addition, lung transplantation is considered as a viable treatment option for eligible patients in the end stage of this pulmonary fibrosis. During past years, there has been a surge in R&D activities that lead to the emergence of potential therapeutic targets and promising drug entrants. Moreover, the market is also experiencing growth by key market player’s expertise.  Collaborations and partnerships between research institutes and pharmaceutical companies to accelerate the development of effective treatment options.

Market snapshot - 2023-2030

Global Market Size

USD 15.2 billion

Largest Segment

Pirfenidone

Fastest Growth

Pirfenidone

Growth Rate

6.13% CAGR

Global Idiopathic Pulmonary Fibrosis Treatment Market ($ Bn)
Country Share for North America Region (%)
Global Idiopathic Pulmonary Fibrosis Treatment Market By Type ($ Bn)
Global Idiopathic Pulmonary Fibrosis Treatment Market By Type (%)

To get more reports on the above market click here to Buy The Report

Global Idiopathic Pulmonary Fibrosis Treatment Market Segmental Analysis

Global Idiopathic Pulmonary Fibrosis Treatment Market is segmented on the basis of type, distribution channel and region. By type, the market is segmented into Pirfenidone and Nintedanib. By distribution channel, it is segmented into hospital pharmacies, retail pharmacies and online providers. By region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa.

Analysis By Type

The largest market segment is pirfenidone segment in the idiopathic pulmonary fibrosis treatment market. Pirfenidone is an anti-fibrotic agent that acts as an anti-inflammatory and antioxidant as well. Additionally, it has been approved by regulatory authorities and is widely used as a standard treatment option for idiopathic pulmonary fibrosis patients. This segment has established efficiency in slowing down the decline in lung function and improving the survival rates of patients that make it the dominating segment in the market.

On the other hand, the Nintedanib segment is experiencing rapid growth, considered as the fastest growing segment in the global idiopathic pulmonary fibrosis treatment market. Nintedanib is in a class of treatments called kinase inhibitors. It works by blocking the action of enzymes involved in affecting fibrosis. Nintedanib has surged in demand and is rapidly accepted due to its favorable safety profile. Nintedanib is a treatment and medication used to slow the rate of decrease in lung function in adults with systemic sclerosis-associated interstitial lung disease.

Analysis By Distribution channel

The dominating segment by distribution channel is hospital pharmacies in the global idiopathic pulmonary fibrosis treatment market. Hospital pharmacies segment plays a crucial role in providing pharmaceutical products and solutions to idiopathic pulmonary fibrosis patients within the hospital and clinics. The pharmacies have direct access to specialized medications such as pirfenidone and nintedanib, which are mostly used in idiopathic pulmonary fibrosis treatment. Hospital pharmacies segment ensure the availability of these treatments and provide professional guidance on its proper usage and administration. 

The fastest growing segment in this market is online providers. The increasing adoption of digital platforms and e-commerce, online providers segment has seen significant growth in recent years. These platforms offer a wide range of idiopathic pulmonary fibrosis treatment options including Nintedanib and Pirfenidone. Additionally, this segment offers doorstep delivery particularly beneficial for patients. The growing trend of telemedicine considerations have contributed to the growth of the online providers segment in the market.

Global Idiopathic Pulmonary Fibrosis Treatment Market By Type, 2021 (%)

To get detailed analysis on other segments, Request For Sample Report

Global Idiopathic Pulmonary Fibrosis Treatment Market Regional Insights

North America dominated the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market based on region. North America has a strong market presence due to factors such as high prevalence of IPF, well-established healthcare infrastructure, advanced diagnostic capabilities, and availability of approved treatment options. Additionally, robust research and development activities, collaborations between academia and industry, and favorable reimbursement policies contribute to the dominant position of North America in the market. The region is also home to key pharmaceutical companies involved in IPF treatment development and commercialization, further consolidating its leading position.

The Asia Pacific region is experiencing growth in various factors such as a large patient pool, increasing awareness about idiopathic pulmonary fibrosis that enhances healthcare infrastructures, and rising healthcare costs. The region has witnessed a growing geriatric population disposed to idiopathic pulmonary fibrosis. In addition, the increasing focus on early diagnosis and treatment as well as the introduction of innovative therapies drive the market growth in Asia Pacific. Moreover, in this region there are so many key market players who play a significant role in the global idiopathic pulmonary fibrosis treatment market by collaborating and partnerships. These factors are enhancing the growth of Asia Pacific in this market.

Global Idiopathic Pulmonary Fibrosis Treatment Market By Geography, 2023-2030
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Global Idiopathic Pulmonary Fibrosis Treatment Market Dynamics

Drivers

Increasing prevalence of IPF

  • One of the key drivers of the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the increasing prevalence of IPF. The rising incidence of IPF globally, particularly among the aging population, is driving the demand for effective treatment options. As the number of diagnosed IPF cases continues to grow, there is a greater need for pharmaceutical interventions and therapies that can slow down disease progression and improve patients' quality of life.

Restraints

High treatment costs

  • One restraint for the idiopathic pulmonary fibrosis market is the high cost of treatment. The cost of this treatment, including medications and diagnostic tests. The high cost of treatment may limit access to effective therapies, mainly in the regions with limited healthcare resources or inadequate insurance coverage. This might be challenging for availability and affordability of treatment.

Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report

Global Idiopathic Pulmonary Fibrosis Treatment Market Competitive Landscape

The global idiopathic pulmonary fibrosis market is described by strong rivalry among key players striving to capture a significant market share. Leading companies are consistently engaged in research and development, product innovation, strategic partnerships, technological advancement and product development to maintain their competitive edge. These industry giants leverage their widespread portfolios to offer a range of solutions, integrating management, and techniques of treatments.

Top Player’s Company Profile

  • GNI Group Ltd

  • Galapagos NV 

  • FibroGen, Inc.

  • GlaxoSmithKline plc

  • F. Hoffmann-La Roche Ltd

  • Shiongi co Ltd

  • Cipla Limited 

  • InterMune, Inc 

  • Phytopharm plc 

  • Mission Therapeutics

  • Biogen, Incorporation

  • Genzyme Corporation 

  • Actelion Pharmaceuticals Ltd 

  • Promedior, Inc

  • MediciNova, Inc 

  • Galecto Biotech AB

  • Celtaxsys, Inc

Recent Developments

  • In April 2022, Bristol-Myers Squibb completed the acquisition of Acceleron Pharma, a company focused on developing therapies for fibrotic diseases including IPF. This acquisition expanded Bristol-Myers Squibb's portfolio of potential IPF treatments.
  • In June 2021, AstraZeneca announced positive results from the Phase 3 ASCEND trial, which demonstrated the efficacy and safety of its IPF treatment, PT010, in reducing disease progression.

Global Idiopathic Pulmonary Fibrosis Treatment Key Market Trends

  • Increasing focus on personalized medicine and precision therapeutics: One of the key trends in the global idiopathic pulmonary fibrosis treatment market is the growing focus on tailored medicine and precision therapeutic. In recent years, the research hotspots of IPF have gradually shifted to its treatment, and significant advancements have been made in pharmacotherapy. Two drugs, Nintedanib and Pirfenidone, have been proven to be safe and effective by slowing the rate of FVC decline and theoretically civilizing the life of patients. These indicate research hotspots in IPF seem to have transferred from pathogenesis to treatment, and from basic medicine to clinical medicine.

Global Idiopathic Pulmonary Fibrosis Treatment Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

According to our Global Idiopathic Pulmonary Fibrosis Treatment Market analysis, The Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is witnessing significant growth driven by factors such as increasing prevalence of IPF, a growing geriatric population, and rising awareness about the disease. The market is dominated by treatments like pirfenidone and nintedanib, which have shown efficacy in slowing down disease progression. The market is segmented based on distribution channels, with hospital pharmacies being the dominant segment and online providers emerging as the fastest-growing segment. North America holds a dominant position in the market, while Asia Pacific is the fastest-growing region. Key drivers include the increasing prevalence of IPF, while the high treatment costs act as a restraint. The market is characterized by intense competition, with companies focusing on research and development, strategic collaborations, and acquisitions. Personalized medicine and precision therapeutics are key trends, aiming to tailor treatment approaches for improved outcomes.

Report Metric Details
Market size value in 2021 USD 15.2 billion
Market size value in 2030 USD 25.96 billion
Growth Rate 6.13%
Base year 2021
Forecast period 2023-2030
Forecast Unit (Value) USD Billion
Segments covered
  • Type
    • Pirfenidone and nintedanib
  • Distribution channel
    • Hospital pharmacies, retail pharmacies and online providers
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • GNI Group Ltd

  • Galapagos NV 

  • FibroGen, Inc.

  • GlaxoSmithKline plc

  • F. Hoffmann-La Roche Ltd

  • Shiongi co Ltd

  • Cipla Limited 

  • InterMune, Inc 

  • Phytopharm plc 

  • Mission Therapeutics

  • Biogen, Incorporation

  • Genzyme Corporation 

  • Actelion Pharmaceuticals Ltd 

  • Promedior, Inc

  • MediciNova, Inc 

  • Galecto Biotech AB

  • Celtaxsys, Inc

Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Global Idiopathic Pulmonary Fibrosis Treatment Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Idiopathic Pulmonary Fibrosis Treatment Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Global Idiopathic Pulmonary Fibrosis Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Idiopathic Pulmonary Fibrosis Treatment Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Idiopathic Pulmonary Fibrosis Treatment Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Global Idiopathic Pulmonary Fibrosis Treatment Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

Global Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 15.2 billion in 2021 and is poised to grow from USD 16.13 billion in 2022 to USD 25.96 billion by 2030, at a CAGR of 6.13% during the forecast period (2023-2030). 

The global idiopathic pulmonary fibrosis market is described by strong rivalry among key players striving to capture a significant market share. Leading companies are consistently engaged in research and development, product innovation, strategic partnerships, technological advancement and product development to maintain their competitive edge. These industry giants leverage their widespread portfolios to offer a range of solutions, integrating management, and techniques of treatments. 'AstraZeneca PLC', 'Bristol-Myers Squibb Company', 'Boehringer Ingelheim', ' GNI Group Ltd ', ' Galapagos NV  ', ' FibroGen, Inc. ', ' GlaxoSmithKline plc ', ' F. Hoffmann-La Roche Ltd ', ' Shiongi co Ltd ', ' Cipla Limited  ', ' InterMune, Inc  ', ' Phytopharm plc  ', ' Mission Therapeutics ', ' Biogen, Incorporation ', ' Genzyme Corporation  ', ' Actelion Pharmaceuticals Ltd  ', ' Promedior, Inc ', ' MediciNova, Inc  ', ' Galecto Biotech AB ', ' Celtaxsys, Inc '

One of the key drivers of the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the increasing prevalence of IPF. The rising incidence of IPF globally, particularly among the aging population, is driving the demand for effective treatment options. As the number of diagnosed IPF cases continues to grow, there is a greater need for pharmaceutical interventions and therapies that can slow down disease progression and improve patients' quality of life.

Increasing focus on personalized medicine and precision therapeutics: One of the key trends in the global idiopathic pulmonary fibrosis treatment market is the growing focus on tailored medicine and precision therapeutic. In recent years, the research hotspots of IPF have gradually shifted to its treatment, and significant advancements have been made in pharmacotherapy. Two drugs, Nintedanib and Pirfenidone, have been proven to be safe and effective by slowing the rate of FVC decline and theoretically civilizing the life of patients. These indicate research hotspots in IPF seem to have transferred from pathogenesis to treatment, and from basic medicine to clinical medicine.

North America dominated the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market based on region. North America has a strong market presence due to factors such as high prevalence of IPF, well-established healthcare infrastructure, advanced diagnostic capabilities, and availability of approved treatment options. Additionally, robust research and development activities, collaborations between academia and industry, and favorable reimbursement policies contribute to the dominant position of North America in the market. The region is also home to key pharmaceutical companies involved in IPF treatment development and commercialization, further consolidating its leading position.

Speak With Our Analyst

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Idiopathic Pulmonary Fibrosis Treatment Market

Product ID: SQMIG35I2261

$5,300
BUY NOW GET SAMPLE